Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1141 to 1152 of 1152 entries
Sorted by: Best Match Show Resources per page
Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities.

Nature communications

Kruse T, Benz C, Garvanska DH, Lindqvist R, Mihalic F, Coscia F, Inturi R, Sayadi A, Simonetti L, Nilsson E, Ali M, Kliche J, Moliner Morro A, Mund A, Andersson E, McInerney G, Mann M, Jemth P, Davey NE, Överby AK, Nilsson J, Ivarsson Y.
PMID: 34799561
Nat Commun. 2021 Nov 19;12(1):6761. doi: 10.1038/s41467-021-26498-z.

Viral proteins make extensive use of short peptide interaction motifs to hijack cellular host factors. However, most current large-scale methods do not identify this important class of protein-protein interactions. Uncovering peptide mediated interactions provides both a molecular understanding of...

Cite
Kruse T, Benz C, Garvanska DH, et al. Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities. Nat Commun. 2021;12(1):6761doi: 10.1038/s41467-021-26498-z.
Kruse, T., Benz, C., Garvanska, D. H., Lindqvist, R., Mihalic, F., Coscia, F., Inturi, R., Sayadi, A., Simonetti, L., Nilsson, E., Ali, M., Kliche, J., Moliner Morro, A., Mund, A., Andersson, E., McInerney, G., Mann, M., Jemth, P., Davey, N. E., Överby, A. K., Nilsson, J., & Ivarsson, Y. (2021). Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities. Nature communications, 12(1), 6761. https://doi.org/10.1038/s41467-021-26498-z
Kruse, Thomas, et al. "Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities." Nature communications vol. 12,1 (2021): 6761. doi: https://doi.org/10.1038/s41467-021-26498-z
Kruse T, Benz C, Garvanska DH, Lindqvist R, Mihalic F, Coscia F, Inturi R, Sayadi A, Simonetti L, Nilsson E, Ali M, Kliche J, Moliner Morro A, Mund A, Andersson E, McInerney G, Mann M, Jemth P, Davey NE, Överby AK, Nilsson J, Ivarsson Y. Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities. Nat Commun. 2021 Nov 19;12(1):6761. doi: 10.1038/s41467-021-26498-z. PMID: 34799561; PMCID: PMC8605023.
Copy Download .nbib Format: NLM
Fate of moderate aortic regurgitation after cardiac surgery.

The Journal of thoracic and cardiovascular surgery

Ward A, Malaisrie SC, Andrei AC, Bonow RO, Thomas JD, Puthumana J, Pham DT, Churyla A, Kruse J, McCarthy PM.
PMID: 33610367
J Thorac Cardiovasc Surg. 2021 Jan 21; doi: 10.1016/j.jtcvs.2020.12.114. Epub 2021 Jan 21.

OBJECTIVE: To determine the prevalence of concomitant aortic regurgitation (AR) in cardiac surgery and the outcomes of treatment options.METHODS: Between April 2004 and June 2018, 3289 patients underwent coronary artery bypass, mitral valve, or aortic aneurysm surgery without aortic...

Cite
Ward A, Malaisrie SC, Andrei AC, et al. Fate of moderate aortic regurgitation after cardiac surgery. J Thorac Cardiovasc Surg. 2021;doi: 10.1016/j.jtcvs.2020.12.114.
Ward, A., Malaisrie, S. C., Andrei, A. C., Bonow, R. O., Thomas, J. D., Puthumana, J., Pham, D. T., Churyla, A., Kruse, J., & McCarthy, P. M. (2021). Fate of moderate aortic regurgitation after cardiac surgery. The Journal of thoracic and cardiovascular surgery, . https://doi.org/10.1016/j.jtcvs.2020.12.114
Ward, Austin, et al. "Fate of moderate aortic regurgitation after cardiac surgery." The Journal of thoracic and cardiovascular surgery vol. (2021). doi: https://doi.org/10.1016/j.jtcvs.2020.12.114
Ward A, Malaisrie SC, Andrei AC, Bonow RO, Thomas JD, Puthumana J, Pham DT, Churyla A, Kruse J, McCarthy PM. Fate of moderate aortic regurgitation after cardiac surgery. J Thorac Cardiovasc Surg. 2021 Jan 21; doi: 10.1016/j.jtcvs.2020.12.114. Epub 2021 Jan 21. PMID: 33610367.
Copy Download .nbib Format: NLM
Considering the value of online support groups for colorectal conditions: perspectives from caregivers and adult patients.

Pediatric surgery international

Judd-Glossy L, Ariefdjohan M, Ketzer J, Matkins K, Schletker J, Krause A, Simmons H, Pena A, De La Torre L, Bischoff A.
PMID: 34562117
Pediatr Surg Int. 2022 Jan;38(1):31-42. doi: 10.1007/s00383-021-05021-x. Epub 2021 Sep 25.

PURPOSE: To evaluate the benefits of participating in an online support group for caregivers of children with a colorectal condition or adult patients with a similar condition.METHODS: An electronic survey was administered to members of an international online support...

Cite
Judd-Glossy L, Ariefdjohan M, Ketzer J, et al. Considering the value of online support groups for colorectal conditions: perspectives from caregivers and adult patients. Pediatr Surg Int. 2021;38(1):31-42doi: 10.1007/s00383-021-05021-x.
Judd-Glossy, L., Ariefdjohan, M., Ketzer, J., Matkins, K., Schletker, J., Krause, A., Simmons, H., Pena, A., De La Torre, L., & Bischoff, A. (2022). Considering the value of online support groups for colorectal conditions: perspectives from caregivers and adult patients. Pediatric surgery international, 38(1), 31-42. https://doi.org/10.1007/s00383-021-05021-x
Judd-Glossy, Laura, et al. "Considering the value of online support groups for colorectal conditions: perspectives from caregivers and adult patients." Pediatric surgery international vol. 38,1 (2022): 31-42. doi: https://doi.org/10.1007/s00383-021-05021-x
Judd-Glossy L, Ariefdjohan M, Ketzer J, Matkins K, Schletker J, Krause A, Simmons H, Pena A, De La Torre L, Bischoff A. Considering the value of online support groups for colorectal conditions: perspectives from caregivers and adult patients. Pediatr Surg Int. 2022 Jan;38(1):31-42. doi: 10.1007/s00383-021-05021-x. Epub 2021 Sep 25. PMID: 34562117; PMCID: PMC8475481.
Copy Download .nbib Format: NLM
Stimuli for Adaptations in Muscle Length and the Length Range of Active Force Exertion-A Narrative Review.

Frontiers in physiology

Kruse A, Rivares C, Weide G, Tilp M, Jaspers RT.
PMID: 34690815
Front Physiol. 2021 Oct 08;12:742034. doi: 10.3389/fphys.2021.742034. eCollection 2021.

Treatment strategies and training regimens, which induce longitudinal muscle growth and increase the muscles' length range of active force exertion, are important to improve muscle function and to reduce muscle strain injuries in clinical populations and in athletes with...

Cite
Kruse A, Rivares C, Weide G, et al. Stimuli for Adaptations in Muscle Length and the Length Range of Active Force Exertion-A Narrative Review. Front Physiol. 2021;12:742034doi: 10.3389/fphys.2021.742034.
Kruse, A., Rivares, C., Weide, G., Tilp, M., & Jaspers, R. T. (2021). Stimuli for Adaptations in Muscle Length and the Length Range of Active Force Exertion-A Narrative Review. Frontiers in physiology, 12742034. https://doi.org/10.3389/fphys.2021.742034
Kruse, Annika, et al. "Stimuli for Adaptations in Muscle Length and the Length Range of Active Force Exertion-A Narrative Review." Frontiers in physiology vol. 12 (2021): 742034. doi: https://doi.org/10.3389/fphys.2021.742034
Kruse A, Rivares C, Weide G, Tilp M, Jaspers RT. Stimuli for Adaptations in Muscle Length and the Length Range of Active Force Exertion-A Narrative Review. Front Physiol. 2021 Oct 08;12:742034. doi: 10.3389/fphys.2021.742034. eCollection 2021. PMID: 34690815; PMCID: PMC8531727.
Copy Download .nbib Format: NLM
[Modern drug therapy for systemic sclerosis associated interstitial lung disease].

Deutsche medizinische Wochenschrift (1946)

Aringer M, Koschel D, Krause A, Schneider U, Gläser S.
PMID: 34861699
Dtsch Med Wochenschr. 2021 Dec 03; doi: 10.1055/a-1658-5176. Epub 2021 Dec 03.

Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD) is associated with an increased risk of morbidity and mortality. Because of a lack of approved medications that can effectively influence SSc-ILD disease course, there is a need for new therapeutic options....

Cite
Aringer M, Koschel D, Krause A, et al. Moderne medikamentöse Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose. [Modern drug therapy for systemic sclerosis associated interstitial lung disease]. Dtsch Med Wochenschr. 2021;doi: 10.1055/a-1658-5176.
Aringer, M., Koschel, D., Krause, A., Schneider, U., & Gläser, S. (2021). Moderne medikamentöse Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose. [Modern drug therapy for systemic sclerosis associated interstitial lung disease]. Deutsche medizinische Wochenschrift (1946), . https://doi.org/10.1055/a-1658-5176
Aringer, Martin, et al. "Moderne medikamentöse Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose." [Modern drug therapy for systemic sclerosis associated interstitial lung disease]. Deutsche medizinische Wochenschrift (1946) vol. (2021). doi: https://doi.org/10.1055/a-1658-5176
Aringer M, Koschel D, Krause A, Schneider U, Gläser S. Moderne medikamentöse Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose. [Modern drug therapy for systemic sclerosis associated interstitial lung disease]. Dtsch Med Wochenschr. 2021 Dec 03; doi: 10.1055/a-1658-5176. Epub 2021 Dec 03. German. PMID: 34861699.
Copy Download .nbib Format: NLM
Adult colloid milium is clinically distinguishable from its histopathologic mimic cutaneous amyloidosis.

Dermatology online journal

Shenoy T, Harber I, Cruse A, Brodell R.
PMID: 34391327
Dermatol Online J. 2021 Jul 15;27(7). doi: 10.5070/D327754362.

Colloid milium, also known as colloid degeneration of the skin or dermal hyalinosis, is a cutaneous deposition disease that presents as three subtypes: juvenile, nodular, and adult. Adult colloid milium is characterized by amyloid-like depositions in the dermis, mimicking...

Cite
Shenoy T, Harber I, Cruse A, et al. Adult colloid milium is clinically distinguishable from its histopathologic mimic cutaneous amyloidosis. Dermatol Online J. 2021;27(7)doi: 10.5070/D327754362.
Shenoy, T., Harber, I., Cruse, A., & Brodell, R. (2021). Adult colloid milium is clinically distinguishable from its histopathologic mimic cutaneous amyloidosis. Dermatology online journal, 27(7), . https://doi.org/10.5070/D327754362
Shenoy, Tanya, et al. "Adult colloid milium is clinically distinguishable from its histopathologic mimic cutaneous amyloidosis." Dermatology online journal vol. 27,7 (2021). doi: https://doi.org/10.5070/D327754362
Shenoy T, Harber I, Cruse A, Brodell R. Adult colloid milium is clinically distinguishable from its histopathologic mimic cutaneous amyloidosis. Dermatol Online J. 2021 Jul 15;27(7). doi: 10.5070/D327754362. PMID: 34391327.
Copy Download .nbib Format: NLM
Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience.

Toxicon: X

Alcoba G, Potet J, Vatrinet R, Singh S, Nanclares C, Kruse A, Den Boer M, Molfino L, Ritmeijer K.
PMID: 35005609
Toxicon X. 2021 Dec 18;13:100089. doi: 10.1016/j.toxcx.2021.100089. eCollection 2022 Mar.

Snakebite envenoming is a public health concern in many countries affected by humanitarian crises. Its magnitude was recognized internationally but associations between snakebite peaks and humanitarian crises were never clearly established or analysed. This scoping review searched any available...

Cite
Alcoba G, Potet J, Vatrinet R, et al. Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience. Toxicon X. 2021;13:100089doi: 10.1016/j.toxcx.2021.100089.
Alcoba, G., Potet, J., Vatrinet, R., Singh, S., Nanclares, C., Kruse, A., Den Boer, M., Molfino, L., & Ritmeijer, K. (2022). Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience. Toxicon: X, 13100089. https://doi.org/10.1016/j.toxcx.2021.100089
Alcoba, Gabriel, et al. "Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience." Toxicon: X vol. 13 (2022): 100089. doi: https://doi.org/10.1016/j.toxcx.2021.100089
Alcoba G, Potet J, Vatrinet R, Singh S, Nanclares C, Kruse A, Den Boer M, Molfino L, Ritmeijer K. Snakebite envenoming in humanitarian crises and migration: A scoping review and the Médecins Sans Frontières experience. Toxicon X. 2021 Dec 18;13:100089. doi: 10.1016/j.toxcx.2021.100089. eCollection 2022 Mar. PMID: 35005609; PMCID: PMC8718667.
Copy Download .nbib Format: NLM
Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key.

Acta clinica Belgica

Saerens M, Kruse V, Lybaert W.
PMID: 33754957
Acta Clin Belg. 2021 Mar 23;1-6. doi: 10.1080/17843286.2021.1903662. Epub 2021 Mar 23.

No abstract available.

Cite
Saerens M, Kruse V, Lybaert W. Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key. Acta Clin Belg. 2021;1-6doi: 10.1080/17843286.2021.1903662.
Saerens, M., Kruse, V., & Lybaert, W. (2021). Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key. Acta clinica Belgica, 1-6. https://doi.org/10.1080/17843286.2021.1903662
Saerens, Michael, et al. "Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key." Acta clinica Belgica vol. (2021): 1-6. doi: https://doi.org/10.1080/17843286.2021.1903662
Saerens M, Kruse V, Lybaert W. Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key. Acta Clin Belg. 2021 Mar 23;1-6. doi: 10.1080/17843286.2021.1903662. Epub 2021 Mar 23. PMID: 33754957.
Copy Download .nbib Format: NLM
COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.

Frontiers in pharmacology

Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO.
PMID: 33833683
Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021.

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or...

Cite
Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol. 2021;12:633680doi: 10.3389/fphar.2021.633680.
Malone, R. W., Tisdall, P., Fremont-Smith, P., Liu, Y., Huang, X. P., White, K. M., Miorin, L., Moreno, E., Alon, A., Delaforge, E., Hennecker, C. D., Wang, G., Pottel, J., Blair, R. V., Roy, C. J., Smith, N., Hall, J. M., Tomera, K. M., Shapiro, G., Mittermaier, A., Kruse, A. C., García-Sastre, A., Roth, B. L., Glasspool-Malone, J., & Ricke, D. O. (2021). COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Frontiers in pharmacology, 12633680. https://doi.org/10.3389/fphar.2021.633680
Malone, Robert W, et al. "COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms." Frontiers in pharmacology vol. 12 (2021): 633680. doi: https://doi.org/10.3389/fphar.2021.633680
Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021. PMID: 33833683; PMCID: PMC8021898.
Copy Download .nbib Format: NLM
Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version.

Zeitschrift fur Rheumatologie

Pfeil A, Krusche M, Vossen D, Berliner MN, Keyßer G, Krause A, Lorenz HM, Manger B, Schuch F, Specker C, Wollenhaupt J, Baraliakos X, Fleck M, Proft F.
PMID: 34605981
Z Rheumatol. 2021 Oct 04; doi: 10.1007/s00393-021-01080-6. Epub 2021 Oct 04.

No abstract available.

Cite
Pfeil A, Krusche M, Vossen D, et al. Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie. Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Z Rheumatol. 2021;doi: 10.1007/s00393-021-01080-6.
Pfeil, A., Krusche, M., Vossen, D., Berliner, M. N., Keyßer, G., Krause, A., Lorenz, H. M., Manger, B., Schuch, F., Specker, C., Wollenhaupt, J., Baraliakos, X., Fleck, M., & Proft, F. (2021). Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie. Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Zeitschrift fur Rheumatologie, . https://doi.org/10.1007/s00393-021-01080-6
Pfeil, Alexander, et al. "Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie." Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Zeitschrift fur Rheumatologie vol. (2021). doi: https://doi.org/10.1007/s00393-021-01080-6
Pfeil A, Krusche M, Vossen D, Berliner MN, Keyßer G, Krause A, Lorenz HM, Manger B, Schuch F, Specker C, Wollenhaupt J, Baraliakos X, Fleck M, Proft F. Mustercurriculum der Deutschen Gesellschaft für Rheumatologie für die Weiterbildung im Fachgebiet Innere Medizin und Rheumatologie. Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. English version. Z Rheumatol. 2021 Oct 04; doi: 10.1007/s00393-021-01080-6. Epub 2021 Oct 04. PMID: 34605981.
Copy Download .nbib Format: NLM
[How is evidence-based medicine defined? Homeopathy-a therapeutic option in medical practice!].

HNO

Weiermayer P, Keusgen M, Pannek J, Panhofer P, Geiger M, Etter-Kalberer G, Tournier AL, Ulbrich Zürni S, Kruse S, Kretzdorn K, Frass M.
PMID: 34919156
HNO. 2022 Jan;70(1):72-74. doi: 10.1007/s00106-021-01122-0. Epub 2021 Dec 17.

No abstract available.

Cite
Weiermayer P, Keusgen M, Pannek J, et al. Wie definiert man evidenzbasierte Medizin? Homöopathie – eine Therapieoption in der Praxis! [How is evidence-based medicine defined? Homeopathy-a therapeutic option in medical practice!]. HNO. 2021;70(1):72-74doi: 10.1007/s00106-021-01122-0.
Weiermayer, P., Keusgen, M., Pannek, J., Panhofer, P., Geiger, M., Etter-Kalberer, G., Tournier, A. L., Ulbrich Zürni, S., Kruse, S., Kretzdorn, K., & Frass, M. (2022). Wie definiert man evidenzbasierte Medizin? Homöopathie – eine Therapieoption in der Praxis! [How is evidence-based medicine defined? Homeopathy-a therapeutic option in medical practice!]. HNO, 70(1), 72-74. https://doi.org/10.1007/s00106-021-01122-0
Weiermayer, Petra, et al. "Wie definiert man evidenzbasierte Medizin? Homöopathie – eine Therapieoption in der Praxis!" [How is evidence-based medicine defined? Homeopathy-a therapeutic option in medical practice!]. HNO vol. 70,1 (2022): 72-74. doi: https://doi.org/10.1007/s00106-021-01122-0
Weiermayer P, Keusgen M, Pannek J, Panhofer P, Geiger M, Etter-Kalberer G, Tournier AL, Ulbrich Zürni S, Kruse S, Kretzdorn K, Frass M. Wie definiert man evidenzbasierte Medizin? Homöopathie – eine Therapieoption in der Praxis! [How is evidence-based medicine defined? Homeopathy-a therapeutic option in medical practice!]. HNO. 2022 Jan;70(1):72-74. doi: 10.1007/s00106-021-01122-0. Epub 2021 Dec 17. German. PMID: 34919156.
Copy Download .nbib Format: NLM
Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial.

Scientific reports

Tiedje D, Borowski M, Simbrich A, Schlößler K, Kruse K, Bothe C, Kuss K, Adarkwah CC, Maisel P, Jendyk R, Kurosinski MA, Gerß J, Tschuschke C, Becker R, Roobol MJ, Bangma CH, Hense HW, Donner-Banzhoff N, Semjonow A.
PMID: 34873188
Sci Rep. 2021 Dec 06;11(1):23503. doi: 10.1038/s41598-021-02696-z.

International guidelines recommend to inform men about the benefits and harms of prostate specific antigen (PSA) based early detection of prostate cancer. This study investigates the influence of a transactional decision aid (DA) or cost compensation (CC) for a...

Cite
Tiedje D, Borowski M, Simbrich A, et al. Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial. Sci Rep. 2021;11(1):23503doi: 10.1038/s41598-021-02696-z.
Tiedje, D., Borowski, M., Simbrich, A., Schlößler, K., Kruse, K., Bothe, C., Kuss, K., Adarkwah, C. C., Maisel, P., Jendyk, R., Kurosinski, M. A., Gerß, J., Tschuschke, C., Becker, R., Roobol, M. J., Bangma, C. H., Hense, H. W., Donner-Banzhoff, N., & Semjonow, A. (2021). Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial. Scientific reports, 11(1), 23503. https://doi.org/10.1038/s41598-021-02696-z
Tiedje, Dorothee, et al. "Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial." Scientific reports vol. 11,1 (2021): 23503. doi: https://doi.org/10.1038/s41598-021-02696-z
Tiedje D, Borowski M, Simbrich A, Schlößler K, Kruse K, Bothe C, Kuss K, Adarkwah CC, Maisel P, Jendyk R, Kurosinski MA, Gerß J, Tschuschke C, Becker R, Roobol MJ, Bangma CH, Hense HW, Donner-Banzhoff N, Semjonow A. Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial. Sci Rep. 2021 Dec 06;11(1):23503. doi: 10.1038/s41598-021-02696-z. PMID: 34873188; PMCID: PMC8648904.
Copy Download .nbib Format: NLM
Showing 1141 to 1152 of 1152 entries